Clinical Trial Update: Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

View source ↗

Summary

A study is evaluating first-line therapy with Sacituzumab Govitecan plus Toripalimab for advanced triple-negative breast cancer, with biomarker exploration; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: TNBC | Status: RECRUITING